摘要
背景:Jak/stat信号通路是生长因子和细胞因子信号传递过程中必不可少的一部分,已成为众多免疫炎症和造血疾病的重要靶点。Spain 西班牙. 目的:本文对JAK/STAT信号通路、JAK/STAT信号通路的结构、生物学功能、作用机制和统计特性进行了综述,并对最新的临床或已批准的J信号通路进行了综述。涉及各种肿瘤和其他免疫标志物的AK抑制剂。此外,最近发现该种抑制剂具有很强的活性或有前途的SE还简要讨论了可选性。 结论:异构体选择性JAK抑制剂的研究与开发已成为该领域的研究热点。在高通量筛选和合理的药物设计的帮助下,越来越多的人JAK抑制剂与改进的选择性配置文件将作为生物探针和药物发现。
关键词: 炎症,JAK,STAT,激酶抑制剂,选择性,信号转导。
图形摘要
Current Drug Targets
Title:JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
Volume: 19 Issue: 5
关键词: 炎症,JAK,STAT,激酶抑制剂,选择性,信号转导。
摘要: Background: JAK/STAT signal pathway, a requisite part in the signaling process of growth factors and cytokines, has become attractive targets for numerous immune, inflammatory and hematopoietic diseases.
Objective: Herein, we present a review of the JAK/STAT signal pathway, the structure, biological function, mechanism of the JAKs and STATs along with a summary of the up-to-date clinical or approved JAK inhibitors which are involved in the treatment of various kinds of tumors and other immunity indications. Moreover, kinds of recently discovered JAKs inhibitors with potent activity or promising selectivity are also briefly discussed.
Conclusion: Research and development of isoform selective JAK inhibitors has become a hot topic in this field. With the assistance of high throughput screening and rational drug design, more and more JAK inhibitors with improved selective profiles will be discovered as biological probes and even therapeutic agents.
Export Options
About this article
Cite this article as:
JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases, Current Drug Targets 2018; 19 (5) . https://dx.doi.org/10.2174/1389450117666161207163054
DOI https://dx.doi.org/10.2174/1389450117666161207163054 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Synthesis and In Vitro Antiproliferative Activity of Thiazole-Based Nitrogen Mustards: The Hydrogen Bonding Interaction between Model Systems and Nucleobases
Anti-Cancer Agents in Medicinal Chemistry Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets Prevalence of Toxoplasma Encephalitis in AIDS Patients Treated with Didanosine Hospitalised in a French Infectious Service
Current HIV Research Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells
Current Drug Targets MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer
Current Cancer Drug Targets Immune Therapy for Infectious Diseases at the Dawn of the 21st Century: the Past, Present and Future Role of Antibody Therapy, Therapeutic Vaccination and Biological Response Modifiers
Current Pharmaceutical Design APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Emulsomes Meet S-layer Proteins: An Emerging Targeted Drug Delivery System
Current Pharmaceutical Biotechnology Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer
Current Drug Targets Retinoids in Clinical Use
Medicinal Chemistry Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design New Insights in Testing and Imaging Techniques for Solid Tumor Response Evaluation
Neuroscience and Biomedical Engineering (Discontinued) Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets